{"entity":{"id":"nct06241781","kind":"trial","name":"Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer","aka":[],"tldr":"A phase 2 trial of Gemcitabine in cervical cancer, run by Grit Biotechnology, now recruiting.","summary":"Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer is a phase 2 interventional study registered as NCT06241781 by Grit Biotechnology, with 83 participants planned, started 2024-04-02 and due to reach its primary completion in 2027-01-31. Interventions recorded: GT101 injection and Gemcitabine injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06241781","url":"https://clinicaltrials.gov/study/NCT06241781"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cervical","recurrent-metastatic-cervical-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["gemcitabine"],"companies":["grit-bio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06241781","phase":"2","setting":"A Phase 2, Multicenter Randomized Controlled Open-label Study of Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer","sponsor":"Grit Biotechnology","participation":[{"nct":"NCT06241781","source":"https://clinicaltrials.gov/study/NCT06241781","fetchedAt":"2026-10-07T16:54:23.000Z","studySha256":"ff007aa1ed2011e3ff459e8b3a0d6550de20176c861e4dbf52087d728905f662","overallStatus":"RECRUITING","lastUpdatePosted":"2026-04-15","leadSponsor":"Grit Biotechnology","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"70 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":83,"enrolmentType":"ESTIMATED","siteCount":24,"recruitingSiteCount":24,"countries":["China"]}],"started":"2024-04-02","startedType":"actual","enrolled":83,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06241781/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"recurrent-metastatic-cervical-cancer","kind":"cancer","name":"Recurrent or metastatic cervical cancer","route":"/cancers/recurrent-metastatic-cervical-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"}],"company":[{"id":"grit-bio","kind":"company","name":"Grit Bio","route":"/companies/grit-bio/"}]}}